NEXTAR - NEXavar as First TARgeted Treatment for Patients With Advanced Renal Cell Carcinoma
Phase of Trial: Phase IV
Latest Information Update: 29 Aug 2016
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms NEXTAR
- Sponsors Bayer
- 28 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jul 2013 New source identified and integrated (German Clinical Trials Register: DRKS00004148).
- 01 Jul 2013 Planned end date changed from 1 Mar 2015 to 1 Mar 2014 as reported by ClinicalTrials.gov.